Aleksandra M. Michalowski, M.Sc., Ph.D.

Aleksandra M. Michalowski, M.Sc., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute


Dr. Michalowski develops biostatistical and bioinformatic approaches for the design and analysis of preclinical cancer research experiments. Her primary focus is genomic studies, which include integration and biological interpretation of large-scale transcriptional signatures from cancer models and patients across a variety of cancer types (multiple myeloma, breast cancer, melanoma and non-melanoma skin cancers, prostate cancer, and lung cancer), modeling of genomic networks, analysis workflows for next-generation sequencing data, and preclinical development of predictive signatures for cancer treatments. Her most recent project involves development of new algorithms for screening of anti-cancer synergistic drug combinations based on high-throughput in vitro assays.

Areas of Expertise

biostatistics, bioinformatics, preclinical


Selected Publications

GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells

Chu IM, Michalowski AM, Hoenerhoff M, Szauter KM, Luger D, Sato M, Flanders K, Oshima A, Csiszar K, Green JE.
Oncogene. 31: 2017-27, 2012. [ Journal Article ]

Investigation into diagnostic agreement using automated computer-assisted histopathology pattern recognition image analysis

Webster JD, Michalowski AM, Dwyer JE, Corps KN, Wei BR, Juopperi T, Hoover SB, Simpson RM.
J Pathol Inform. 3: 18, 2012. [ Journal Article ]

A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells

Lee KH, Li M, Michalowski AM, Zhang X, Liao H, Chen L, Xu Y, Wu X, Huang J.
Proc. Natl. Acad. Sci. U.S.A.. 107: 69-74, 2010. [ Journal Article ]

TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms

Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR, Sullivan P, Gamache B, Felsenstein K, Kuehl WM, Simpson RM, Zingone A, Landgren O, Mock BA.
Mol Oncol. 8: 261-72, 2014. [ Journal Article ]

Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer

Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE.
Breast Cancer Res.. 14: R109, 2012. [ Journal Article ]